Patient Research for RRMS – Newly diagnosed and switchers of medications

Patient Research for RRMS – oral or injectables.

Find a Cure Panel (FACP)  specializes in patient research for rare and serious diseases and has some upcoming research for people with MS

This research focuses on your decision for which treatment you commenced (i.e. oral vs. injectable vs. infusion) as well as reasons for switching or potentially switching to another treatment and the decision calculus for such switch.

To qualify for this survey, you must meet the following qualifications:

• Have RRMS and be on oral (Aubagio, Gilenya, Tecfidera, etc.) or injectable (Avonex, Betaseron, Copaxone, Rebif, etc.).  If you are on an infusion (Tysabri, Ocrevus) you will NOT qualify.
• Be on your first MS treatment unless you recently switched to a second treatment.  

This research is very easy to participate in. It’s one call with one moderator talking about your experience.

FACP gives you a 1-800 number and schedules the call at your convenience and if you do the call, FACP will donate $200 to MS Views and News (MSVN).

If you are interested in participating, please email info@findacurepanel.com  (yes, this is a corrected email address) and reference MSVN.

Doug Lowell
President, Sample Czar
1850 Industrial Street, Suite 514
Los Angeles, CA 90021
direct: 323-717-8117
em: dlowell@sampleczar.com  
im: sampleczarlowell@skype.com

=======================================

Disclaimer:
MS Views and News is only providing the information for this research study.

We will not be involved in the activity nor the results.